Symbols / BCAB Stock $4.59 +1.77% BioAtla, Inc.

Healthcare • Biotechnology • United States • NCM
BCAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jay M. Short Ph.D.
Exch · Country NCM · United States
Market Cap 7.61M
Enterprise Value 6.55M
Income -59.61M
Sales 2.00M
FCF (ttm) -22.80M
Book/sh -28.51
Cash/sh 4.30
Employees 41
Insider 10d —
IPO Dec 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.43
PEG —
P/S 3.80
P/B -0.16
P/C —
EV/EBITDA -0.11
EV/Sales 3.28
Quick Ratio 0.33
Current Ratio 0.37
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -50.50
EPS next Y -1.34
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2025-11-13
ROA -110.76%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin -4.63%
Profit Margin 0.00%
Shs Outstand 1.66M
Shs Float 1.38M
Insider Own 5.63%
Instit Own 19.51%
Short Float 7.20%
Short Ratio 2.48
Short Interest 113.26K
52W High 71.50
vs 52W High -93.58%
52W Low 3.92
vs 52W Low 17.09%
Beta 1.21
Impl. Vol. 0.00%
Rel Volume 0.13
Avg Volume 48.58K
Volume 6.42K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $4.51
Price $4.59
Change 1.77%
About

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$4.58
Latest analyst target
3. DCF / Fair value
$-247.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.58
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-13 down JMP Securities Market Outperform → Market Perform —
2025-03-31 main Citizens Capital Markets Market Outperform → Market Outperform $1
2025-03-31 reit HC Wainwright & Co. Neutral → Neutral —
2024-11-13 down HC Wainwright & Co. Buy → Neutral —
2024-09-16 reit JMP Securities Market Outperform → Market Outperform $5
2024-05-23 main JMP Securities Market Outperform → Market Outperform $5
2024-05-15 reit HC Wainwright & Co. Buy → Buy $7
2024-03-28 reit JMP Securities Market Outperform → Market Outperform $12
2024-03-27 main HC Wainwright & Co. Buy → Buy $7
2023-12-05 reit JMP Securities Market Outperform → Market Outperform $12
2023-11-08 main HC Wainwright & Co. Buy → Buy $10
2023-09-25 main JP Morgan Overweight → Overweight $14
2023-08-02 main JP Morgan Overweight → Overweight $17
2023-08-02 reit JMP Securities Market Outperform → Market Outperform $12
2023-08-02 reit EF Hutton Buy → Buy $25
2023-08-02 reit HC Wainwright & Co. Buy → Buy $17
2023-05-15 reit JMP Securities Outperform → Outperform $12
2023-05-15 reit HC Wainwright & Co. Buy → Buy $17
2023-05-12 reit EF Hutton Buy → Buy $25
2023-04-17 main EF Hutton — → Buy $25
News
RSS: Latest BCAB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-11 SHORT JAY M Chief Executive Officer — 430,000 $0.00 $0
2026-03-10 VASQUEZ CHRISTIAN J Chief Financial Officer — 240,000 $0.00 $0
2026-03-10 SIEVERS ERIC L Officer — 240,000 $0.00 $0
2025-06-18 STEINMAN LAWRENCE Director — 23,500 $0.00 $0
2025-06-18 MORAN SUSAN Director — 23,500 $0.00 $0
2025-06-18 GRAY MARY ANN Director — 23,500 $0.00 $0
2025-06-18 MCBRINN SYLVIA Director — 23,500 $0.00 $0
2025-06-18 SMITH SCOTT ANDREW Director — 23,500 $0.00 $0
2025-06-18 WILLIAMS EDDIE Director — 23,500 $0.00 $0
2025-03-12 SHORT JAY M Chief Executive Officer — 431,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.00
-81.82%
11.00
0.00
0.00
Operating Revenue
2.00
-81.82%
11.00
0.00
0.00
Operating Expense
61.30
-27.83%
84.94
-34.50%
129.69
+19.93%
108.14
Research And Development
43.57
-30.94%
63.09
-39.17%
103.73
+30.73%
79.35
Selling General And Administration
17.73
-18.84%
21.85
-15.83%
25.96
-9.85%
28.79
General And Administrative Expense
17.73
-18.84%
21.85
-15.83%
25.96
-9.85%
28.79
Other Gand A
17.73
-18.84%
21.85
-15.83%
25.96
-9.85%
28.79
Total Expenses
61.30
-27.83%
84.94
-34.50%
129.69
+19.93%
108.14
Operating Income
-59.30
+19.80%
-73.94
+42.98%
-129.69
-19.93%
-108.14
Total Operating Income As Reported
-59.30
+19.80%
-73.94
+42.98%
-129.69
-19.93%
-108.14
EBITDA
-58.93
+19.29%
-73.02
+43.16%
-128.47
-20.13%
-106.94
Normalized EBITDA
-59.23
+19.77%
-73.83
+42.53%
-128.47
-20.13%
-106.94
Reconciled Depreciation
0.37
-59.68%
0.93
-24.24%
1.22
+1.83%
1.20
EBIT
-59.30
+19.80%
-73.94
+42.98%
-129.69
-19.93%
-108.14
Total Unusual Items
0.29
-63.44%
0.81
—
0.00
Total Unusual Items Excluding Goodwill
0.29
-63.44%
0.81
—
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Pretax Income
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Net Non Operating Interest Income Expense
0.84
-74.98%
3.37
-46.63%
6.31
+283.01%
1.65
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.84
-74.98%
3.37
-46.63%
6.31
+283.01%
1.65
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.84
-74.98%
3.37
-46.63%
6.31
+283.01%
1.65
Interest Income
0.84
-74.98%
3.37
-46.63%
6.31
+283.01%
1.65
Other Income Expense
-1.15
-243.48%
0.80
+1017.24%
-0.09
-970.00%
0.01
Other Non Operating Income Expenses
-1.44
-15900.00%
-0.01
+89.66%
-0.09
-970.00%
0.01
Gain On Sale Of Security
0.29
-63.44%
0.81
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Net Income From Continuing Operation Net Minority Interest
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Net Income From Continuing And Discontinued Operation
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Net Income Continuous Operations
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Minority Interests
—
—
—
—
Normalized Income
-59.90
+15.13%
-70.58
+42.83%
-123.46
-15.95%
-106.48
Net Income Common Stockholders
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Diluted EPS
-1.01
+98.32%
-60.05
+53.45%
-129.00
-159.10%
-49.79
Basic EPS
-1.01
+98.32%
-60.05
+53.45%
-129.00
-159.10%
-49.79
Basic Average Shares
58.83
+4962.72%
1.16
+21.60%
0.96
-55.32%
2.14
Diluted Average Shares
58.83
+4962.72%
1.16
+21.60%
0.96
-55.32%
2.14
Diluted NI Availto Com Stockholders
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
13.83
-73.62%
52.42
-56.19%
119.66
-46.99%
225.74
Current Assets
8.01
-84.36%
51.23
-55.99%
116.41
-47.19%
220.43
Cash Cash Equivalents And Short Term Investments
7.12
-85.49%
49.05
-56.00%
111.47
-48.27%
215.51
Cash And Cash Equivalents
7.12
-85.49%
49.05
-56.00%
111.47
-48.27%
215.51
Prepaid Assets
0.66
-61.87%
1.74
-62.32%
4.62
+5.25%
4.38
Other Current Assets
0.23
-48.10%
0.45
+39.69%
0.32
-40.63%
0.54
Total Non Current Assets
5.82
+388.66%
1.19
-63.41%
3.25
-38.70%
5.30
Net PPE
5.65
+374.96%
1.19
-61.59%
3.10
-39.86%
5.15
Gross PPE
10.96
+33.77%
8.19
-10.71%
9.18
-12.73%
10.52
Accumulated Depreciation
-5.31
+24.20%
-7.00
-15.22%
-6.08
-13.31%
-5.36
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.10
-36.03%
1.72
+0.00%
1.72
-19.58%
2.14
Other Properties
7.36
+163.65%
2.79
-26.04%
3.77
-19.48%
4.69
Leases
2.50
-32.12%
3.68
+0.00%
3.68
-0.19%
3.69
Other Non Current Assets
0.16
—
0.15
+0.00%
0.15
Total Liabilities Net Minority Interest
50.02
+31.08%
38.16
-22.11%
48.99
+7.91%
45.40
Current Liabilities
21.92
+50.77%
14.54
-48.70%
28.34
+22.54%
23.13
Payables And Accrued Expenses
16.32
+48.62%
10.98
-52.12%
22.93
+26.27%
18.16
Payables
8.19
+330.81%
1.90
-50.20%
3.82
-9.74%
4.23
Accounts Payable
8.19
+330.81%
1.90
-50.20%
3.82
-9.74%
4.23
Current Accrued Expenses
8.12
-10.51%
9.08
-52.51%
19.11
+37.21%
13.93
Pensionand Other Post Retirement Benefit Plans Current
0.04
-98.64%
2.73
-28.07%
3.79
+9.82%
3.45
Current Debt And Capital Lease Obligation
1.43
+70.69%
0.84
-48.52%
1.62
+6.77%
1.52
Current Capital Lease Obligation
1.43
+70.69%
0.84
-48.52%
1.62
+6.77%
1.52
Current Deferred Liabilities
4.14
0.00
—
—
Current Deferred Revenue
—
—
—
—
Total Non Current Liabilities Net Minority Interest
28.09
+18.96%
23.62
+14.41%
20.64
-7.29%
22.27
Long Term Debt And Capital Lease Obligation
4.77
0.00
-100.00%
0.84
-66.02%
2.46
Long Term Capital Lease Obligation
4.77
0.00
-100.00%
0.84
-66.02%
2.46
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
—
—
—
—
Other Non Current Liabilities
19.81
+0.00%
19.81
+0.00%
19.81
+0.00%
19.81
Stockholders Equity
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Common Stock Equity
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Capital Stock
0.01
+0.00%
0.01
+20.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+20.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
1.27
+9.23%
1.16
+20.84%
0.96
-55.04%
2.14
Ordinary Shares Number
1.27
+9.23%
1.16
+20.84%
0.96
-55.04%
2.14
Additional Paid In Capital
509.45
+1.83%
500.30
+2.75%
486.93
+2.92%
473.13
Retained Earnings
-545.65
-12.26%
-486.04
-16.76%
-416.26
-42.17%
-292.80
Total Equity Gross Minority Interest
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Total Capitalization
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Working Capital
-13.91
-137.91%
36.69
-58.33%
88.06
-55.37%
197.30
Invested Capital
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Total Debt
6.20
+641.63%
0.84
-66.02%
2.46
-38.21%
3.98
Capital Lease Obligations
6.20
+641.63%
0.84
-66.02%
2.46
-38.21%
3.98
Net Tangible Assets
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Tangible Book Value
-36.19
-353.69%
14.27
-79.82%
70.67
-60.81%
180.34
Derivative Product Liabilities
3.52
-7.74%
3.81
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-48.20
+32.99%
-71.94
+30.84%
-104.02
-15.04%
-90.42
Cash Flow From Continuing Operating Activities
-48.20
+32.99%
-71.94
+30.84%
-104.02
-15.04%
-90.42
Net Income From Continuing Operations
-59.61
+14.57%
-69.78
+43.48%
-123.46
-15.95%
-106.48
Depreciation Amortization Depletion
0.37
-59.68%
0.93
-24.24%
1.22
+1.83%
1.20
Depreciation And Amortization
0.37
-59.68%
0.93
-24.24%
1.22
+1.83%
1.20
Other Non Cash Items
1.02
—
—
—
Stock Based Compensation
5.43
-39.09%
8.92
-34.13%
13.54
-7.00%
14.56
Operating Gains Losses
-0.11
+86.37%
-0.81
-40450.00%
0.00
-84.62%
0.01
Gain Loss On Investment Securities
-0.29
+63.44%
-0.81
—
—
Unrealized Gain Loss On Investment Securities
0.41
0.00
—
—
Gain Loss On Sale Of PPE
0.18
0.00
-100.00%
0.00
-84.62%
0.01
Change In Working Capital
4.28
+138.18%
-11.20
-339.29%
4.68
+1530.66%
0.29
Change In Prepaid Assets
1.13
-61.14%
2.90
+26490.91%
-0.01
+99.58%
-2.61
Change In Payables And Accrued Expense
2.80
+120.83%
-13.46
-354.75%
5.28
+54.91%
3.41
Change In Payable
—
—
5.28
+54.91%
3.41
Change In Account Payable
—
—
5.28
+54.91%
3.41
Change In Other Working Capital
0.34
+153.67%
-0.64
-8.09%
-0.59
-15.59%
-0.51
Investing Cash Flow
—
0.00
+100.00%
-0.10
+63.02%
-0.27
Cash Flow From Continuing Investing Activities
—
0.00
+100.00%
-0.10
+63.02%
-0.27
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.10
+63.02%
-0.27
Purchase Of PPE
—
0.00
+100.00%
-0.10
+63.43%
-0.27
Sale Of PPE
—
—
0.00
-100.00%
0.00
Capital Expenditure
—
—
-0.10
+63.43%
-0.27
Financing Cash Flow
6.28
-34.01%
9.51
+12251.95%
0.08
-99.87%
61.21
Cash Flow From Continuing Financing Activities
6.28
-34.01%
9.51
+12251.95%
0.08
-99.87%
61.21
Net Issuance Payments Of Debt
7.12
0.00
—
—
Issuance Of Debt
7.12
0.00
—
—
Long Term Debt Issuance
7.12
0.00
—
—
Net Long Term Debt Issuance
7.12
0.00
—
—
Net Common Stock Issuance
0.00
-100.00%
9.21
0.00
-100.00%
61.68
Proceeds From Stock Option Exercised
0.10
-70.76%
0.34
+1.79%
0.34
+16.26%
0.29
Net Other Financing Charges
-0.95
-1963.04%
-0.05
+82.24%
-0.26
+65.83%
-0.76
Changes In Cash
-41.93
+32.83%
-62.42
+40.00%
-104.04
-253.00%
-29.47
Beginning Cash Position
49.05
-56.00%
111.47
-48.27%
215.51
-12.03%
244.98
End Cash Position
7.12
-85.49%
49.05
-56.00%
111.47
-48.27%
215.51
Free Cash Flow
-48.20
+32.99%
-71.94
+30.91%
-104.11
-14.80%
-90.69
Income Tax Paid Supplemental Data
—
0.00
-100.00%
0.01
-91.04%
0.07
Common Stock Issuance
0.00
-100.00%
9.21
0.00
-100.00%
61.68
Issuance Of Capital Stock
0.00
-100.00%
9.21
0.00
-100.00%
61.68
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category